JPRN-UMIN000004822
Completed
Phase 2
A phase II study of first-line gefitinib for advanced and recurrent EGFR mutation positivenon-small cell lung cancerwith high-risk factors - A phase II study of first-line gefitinib for advanced and recurrent EGFR mutation positivenon-small cell lung cancerwith high-risk factors
Conditionsnon-small cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- non-small cell lung cancer
- Sponsor
- Kanagawa Cancer Center
- Enrollment
- 37
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)ECOG Perfomance Status 4 2\)white blood cell count; less than 2,000/mm3 3\)bsolute neutrophil count; less than 1,000/mm3 4\)hemoglobin; less than 7\.0 g/dL 5\)platelet count; less than 75,000/mm3 6\)serum total bilirubin; 1\.5 mg/dL or over 7\)AST/ALT; 100 IU/L or over 8\)serum creatinine; 1\.5 mg/dL or over 9\)serious complications below I)uncontrollable angina pectoris, myocardial infarction within 6 months or heart failure II)serious heart dosease III)uncontrollable diabetes or hypertension IV)infection 10\)pulmonary fibrosis or interstitial pneumonitis evident on chest X ray 11\)now pregnant or lactation, or possible pregnancy or refusal of contraception 12\)difficult to perform or continue of this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutationslung adenocarcinomaJPRN-UMIN000002783agano lung cancer study meeting15
Completed
Phase 2
phase II study of gefitinib as a first-line therapy in elderly patients with lung adenocarcinoma.JPRN-C000000136West Japan Oncology Group30
Completed
Phase 2
A Phase II study of Gefitinib as First-Line Treatment for Elderly Patients with Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.on-Small-Cell Lung CancerJPRN-UMIN000001863Central Japan Lung Study Group19
Completed
Phase 2
Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutationsnon-small cell lung cancerJPRN-C000000184Hokkaido Lung Cancer Clinical Study Group16
Recruiting
Phase 1
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancerACTRN12605000510640peter maccallum Cancer Centre70